Shares of Novavax Inc. NVAX rallied 6.11% to $6.34 Monday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index COMP rising 4.35% to ...

Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...

Novavax Inc (NVAX) reports a dramatic revenue increase and strategic collaborations, while navigating regulatory hurdles and ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

According to TipRanks.com, Werber is a 4-star analyst with an average return of 7.6% and a 49.5% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are ...